Parse Biosciences and Graph Therapeutics have entered into a strategic partnership to build one of the largest and most comprehensive immune cell perturbation atlases to date. The collaboration combines Graph’s lab-in-the-loop AI platform with Parse’s GigaLab to profile hundreds of millions of immune cells from patients with immune-mediated diseases under systematic perturbation.

The initiative aims to make the immune system’s highly dynamic and patient-specific behaviour accessible to AI-first drug discovery, enabling faster and more reliable identification of drug targets while reducing late-stage clinical failure risk. By generating clinically relevant, large-scale single-cell datasets, the partnership seeks to accelerate the development of curative therapies for immune-mediated diseases.

Autoimmune and inflammatory disorders are driven by complex, context-dependent immune cell responses that vary across patients, posing major challenges for drug developers. The Graph–Parse collaboration addresses this by combining realistic patient-derived disease models with scalable whole-transcriptome single-cell sequencing to map immune and tissue interactions at unprecedented scale.

Graph’s platform integrates primary patient cell assays with iterative active-learning approaches that systematically select and test perturbations across disease-relevant conditions. Each experimental cycle informs the next, enabling rapid elimination of non-viable hypotheses and creating a compounding knowledge base that improves discovery efficiency.

Once Graph’s platform determines the most informative disease contexts to study, Parse’s GigaLab—powered by Evercode technology—will generate high-quality, large-scale single-cell datasets with exceptional speed and consistency.

Gregory Vladimer, PhD, Chief Executive Officer and Co-founder of Graph Therapeutics, said the partnership reflects a data-infrastructure-driven approach to drug discovery, designed to reduce biological uncertainty early and fundamentally improve development economics and success rates.

Charlie Roco, PhD, Co-founder and Chief Technology Officer of Parse Biosciences, said the collaboration demonstrates how industrial-scale single-cell biology combined with advanced AI can uncover disease mechanisms directly in patient cells and transform drug discovery.

Graph Therapeutics is developing a next-generation AI-enabled platform focused on inflammation and immunology, building on prior successes in precision oncology. Parse Biosciences is a global life sciences company dedicated to advancing human health by enabling large-scale, accessible single-cell sequencing across a wide range of disease areas.